Jo A Van Ginderachter

List of Publications by Year
in descending order

141 papers	16,490 citations	41258 49 h-index	16605 123 g-index
147 all docs	147 docs citations	147 times ranked	26240 citing authors

#	Article	IF	Citations
1	Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. Immunity, 2014, 41, 14-20.	6.6	4,638
2	Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cellâ€“suppressive activity. Blood, 2008, 111, 4233-4244.	0.6	1,081
3	Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) Monocytes. Cancer Research, 2010, 70, 5728-5739.	0.4	1,018
4	HRG Inhibits Tumor Growth and Metastasis by Inducing Macrophage Polarization and Vessel Normalization through Downregulation of PlGF. Cancer Cell, 2011, 19, 31-44.	7.7	628
5	A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment. Nature Neuroscience, 2019, 22, 1021-1035.	7.1	603
6	Impeding Macrophage Entry into Hypoxic Tumor Areas by Sema3A/Nrp1 Signaling Blockade Inhibits Angiogenesis and Restores Antitumor Immunity. Cancer Cell, 2013, 24, 695-709.	7.7	505
7	Tumor Hypoxia Does Not Drive Differentiation of Tumor-Associated Macrophages but Rather Fine-Tunes the M2-like Macrophage Population. Cancer Research, 2014, 74, 24-30.	0.4	348
8	Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. Nature, 2019, 566, 403-406.	13.7	326
9	Classical and alternative activation of mononuclear phagocytes: Picking the best of both worlds for tumor promotion. Immunobiology, 2006, 211, 487-501.	0.8	309
10	Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nature Neuroscience, 2021, 24, 595-610.	7.1	288
11	Nanobody-Based Targeting of the Macrophage Mannose Receptor for Effective <i>In Vivo</i> Imaging of Tumor-Associated Macrophages. Cancer Research, 2012, 72, 4165-4177.	0.4	263
12	Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. International Journal of Developmental Biology, 2011, 55, 861-867.	0.3	255
13	Molecular Profiling Reveals a Tumor-Promoting Phenotype of Monocytes and Macrophages in Human Cancer Progression. Immunity, 2014, 41, 815-829.	6.6	240
14	Macrophage Metabolism As Therapeutic Target for Cancer, Atherosclerosis, and Obesity. Frontiers in Immunology, 2017, 8, 289.	2.2	225
15	The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. Nature Communications, 2016, 7, 13720.	5.8	217
16	M-CSF and GM-CSF Receptor Signaling Differentially Regulate Monocyte Maturation and Macrophage Polarization in the Tumor Microenvironment. Cancer Research, 2016, 76, 35-42.	0.4	184
17	The Transcription Factor ZEB2 Is Required to Maintain the Tissue-Specific Identities of Macrophages. Immunity, 2018, 49, 312-325.e5.	6.6	172
18	Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression. Frontiers in Immunology, 2014, 5, 489.	2.2	163

#	Article	IF	Citations
19	Mechanisms Driving Macrophage Diversity and Specialization in Distinct Tumor Microenvironments and Parallelisms with Other Tissues. Frontiers in Immunology, 2014, 5, 127.	2.2	162
20	Identification of a common gene signature for type II cytokineâ€"associated myeloid cells elicited in vivo in different pathologic conditions. Blood, 2006, 108, 575-583.	0.6	155
21	Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. ELife, 2020, 9, .	2.8	154
22	Podoplanin-Expressing Macrophages Promote Lymphangiogenesis and Lymphoinvasion in Breast Cancer. Cell Metabolism, 2019, 30, 917-936.e10.	7.2	150
23	PET Imaging of Macrophage Mannose Receptorâ€"Expressing Macrophages in Tumor Stroma Using ¹⁸F-Radiolabeled Camelid Single-Domain Antibody Fragments. Journal of Nuclear Medicine, 2015, 56, 1265-1271.	2.8	139
24	Regulation and function of the E-cadherin/catenin complex in cells of the monocyte-macrophage lineage and DCs. Blood, 2012, 119, 1623-1633.	0.6	138
25	Acute injury in the peripheral nervous system triggers an alternative macrophage response. Journal of Neuroinflammation, 2012, 9, 176.	3.1	134
26	Peroxisome proliferator-activated receptor Î³ (PPARÎ³) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood, 2006, 108, 525-535.	0.6	114
27	How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions. Cancer Immunology, Immunotherapy, 2019, 68, 631-644.	2.0	110
28	IL-10 Dampens TNF/Inducible Nitric Oxide Synthase-Producing Dendritic Cell-Mediated Pathogenicity during Parasitic Infection. Journal of Immunology, 2009, 182, 1107-1118.	0.4	108
29	Myeloidâ€derived suppressor cells in parasitic infections. European Journal of Immunology, 2010, 40, 2976-2985.	1.6	107
30	Alternatively activated macrophages engage in homotypic and heterotypic interactions through IL-4 and polyamine-induced E-cadherin/catenin complexes. Blood, 2009, 114, 4664-4674.	0.6	103
31	Pivotal Advance: Arginase-1-independent polyamine production stimulates the expression of IL-4-induced alternatively activated macrophage markers while inhibiting LPS-induced expression of inflammatory genes. Journal of Leukocyte Biology, 2012, 91, 685-699.	1.5	100
32	Nitric Oxide-Independent CTL Suppression during Tumor Progression: Association with Arginase-Producing (M2) Myeloid Cells. Journal of Immunology, 2003, 170, 5064-5074.	0.4	95
33	G-CSF stem cell mobilization in human donors induces polymorphonuclear and mononuclear myeloid-derived suppressor cells. Clinical Immunology, 2012, 143, 83-87.	1.4	95
34	Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies. Frontiers in Oncology, 2014, 4, 349.	1.3	92
35	Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 23-34.	3.3	90
36	Mononuclear phagocyte heterogeneity in cancer: Different subsets and activation states reaching out at the tumor site. Immunobiology, 2011, 216, 1192-1202.	0.8	88

#	Article	IF	Citations
37	The active enhancer network operated by liganded RXR supports angiogenic activity in macrophages. Genes and Development, 2014, 28, 1562-1577.	2.7	85
38	CCR2-dependent monocyte-derived macrophages resolve inflammation and restore gut motility in postoperative ileus. Gut, 2017, 66, 2098-2109.	6.1	78
39	Assessment of stability, toxicity and immunogenicity of new polymeric nanoreactors for use in enzyme replacement therapy of MNGIE. Journal of Controlled Release, 2009, 137, 246-254.	4.8	75
40	Tumorâ€induced myeloidâ€derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct <scp>CD</scp>8⁺<scp>T</scp>â€cell activation events. European Journal of Immunology, 2013, 43, 2930-2942.	1.6	73
41	Immune Evasion Strategies of Trypanosoma brucei within the Mammalian Host: Progression to Pathogenicity. Frontiers in Immunology, 2016, 7, 233.	2.2	72
42	Clinical Translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT Imaging of Protumorigenic Macrophages. Molecular Imaging and Biology, 2019, 21, 898-906.	1.3	69
43	Macrophages are metabolically heterogeneous within the tumor microenvironment. Cell Reports, 2021, 37, 110171.	2.9	69
44	Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow. Leukemia, 2012, 26, 2424-2428.	3.3	67
45	African Trypanosomiasis-Associated Anemia: The Contribution of the Interplay between Parasites and the Mononuclear Phagocyte System. Frontiers in Immunology, 2018, 9, 218.	2.2	67
46	Instruction of myeloid cells by the tumor microenvironment: Open questions on the dynamics and plasticity of different tumor-associated myeloid cell populations. OncoImmunology, 2012, 1, 1135-1145.	2.1	66
47	Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy. , 2019, 7, 10.		66
48	Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells. Oncotarget, 2015, 6, 10532-10547.	0.8	64
49	Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition. , 2019, 7, 216.		56
50	Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. Immunity, 2014, 41, 339-340.	6.6	53
51	Novel insights in the regulation and function of macrophages in the tumor microenvironment. Current Opinion in Oncology, 2017, 29, 55-61.	1.1	53
52	Targeting Protumoral Tumor-Associated Macrophages with Nanobody-Functionalized Nanogels through Strain Promoted Azide Alkyne Cycloaddition Ligation. Bioconjugate Chemistry, 2018, 29, 2394-2405.	1.8	51
53	Tumourâ€associated macrophageâ€mediated survival of myeloma cells through <scp>STAT3</scp> activation. Journal of Pathology, 2017, 241, 534-546.	2.1	50
54	Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies. Journal of Clinical Investigation, 2018, 128, 3976-3990.	3.9	50

#	Article	IF	Citations
55	Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway. Cancer Letters, 2019, 442, 233-241.	3.2	49
56	IL1Î² Promotes Immune Suppression in the Tumor Microenvironment Independent of the Inflammasome and Gasdermin D. Cancer Immunology Research, 2021, 9, 309-323.	1.6	48
57	Estrogen Receptor Î± Regulates Î²-Cell Formation During Pancreas Development and Following Injury. Diabetes, 2015, 64, 3218-3228.	0.3	47
58	In Vivo Inhibition of c-MYC in Myeloid Cells Impairs Tumor-Associated Macrophage Maturation and Pro-Tumoral Activities. PLoS ONE, 2012, 7, e45399.	1.1	46
59	MIF Contributes to Trypanosoma brucei Associated Immunopathogenicity Development. PLoS Pathogens, 2014, 10, e1004414.	2.1	45
60	Macrophage dynamics are regulated by local macrophage proliferation and monocyte recruitment in injured pancreas. European Journal of Immunology, 2015, 45, 1482-1493.	1.6	45
61	The Ontogeny and Microenvironmental Regulation of Tumor-Associated Macrophages. Antioxidants and Redox Signaling, 2016, 25, 775-791.	2.5	45
62	The non-mammalian MIF superfamily. Immunobiology, 2017, 222, 473-482.	0.8	43
63	Identifying the variables that drive tamoxifenâ€independent CreERT2 recombination: Implications for microglial fate mapping and gene deletions. European Journal of Immunology, 2020, 50, 459-463.	1.6	43
64	Antagonistic effect of NK cells on alternatively activated monocytes: a contribution of NK cells to CTL generation. Blood, 2002, 100, 4049-4058.	0.6	42
65	Interactions among myeloid regulatory cells in cancer. Cancer Immunology, Immunotherapy, 2019, 68, 645-660.	2.0	42
66	Macrophages, PPARs, and Cancer. PPAR Research, 2008, 2008, 1-11.	1.1	41
67	Modulation of CD8+ T-cell activation events by monocytic and granulocytic myeloid-derived suppressor cells. Immunobiology, 2013, 218, 1385-1391.	0.8	41
68	The role of hepatic macrophages in liver metastasis. Cellular Immunology, 2018, 330, 202-215.	1.4	39
69	Functional characterization of in vivo effector CD4+ and CD8+ T cell responses in acute Toxoplasmosis: An interplay of IFN-Î³ and cytolytic T cells. Vaccine, 2010, 28, 2556-2564.	1.7	38
70	Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer. Immunobiology, 2012, 217, 1266-1272.	0.8	38
71	Targeted Repolarization of Tumorâ€Associated Macrophages via Imidazoquinolineâ€Linked Nanobodies. Advanced Science, 2021, 8, 2004574.	5.6	38
72	Concise Review: Macrophages: Versatile Gatekeepers During Pancreatic Î²-Cell Development, Injury, and Regeneration. Stem Cells Translational Medicine, 2015, 4, 555-563.	1.6	34

#	Article	IF	Citations
73	High Salt Inhibits Tumor Growth by Enhancing Anti-tumor Immunity. Frontiers in Immunology, 2019, 10, 1141.	2.2	34
74	Neutrophils enhance early Trypanosoma brucei infection onset. Scientific Reports, 2018, 8, 11203.	1.6	33
75	Exploiting tumor-associated dendritic cell heterogeneity for novel cancer therapies. Journal of Leukocyte Biology, 2017, 102, 317-324.	1.5	32
76	Paracrine interactions of cancer-associated fibroblasts, macrophages and endothelial cells: tumor allies and foes. Current Opinion in Oncology, 2018, 30, 45-53.	1.1	32
77	Hypoxia and tumor-associated macrophages. OncoImmunology, 2014, 3, e27561.	2.1	30
78	Subset characterization of myeloid-derived suppressor cells arising during induction of BM chimerism in mice. Bone Marrow Transplantation, 2012, 47, 985-992.	1.3	29
79	E-cadherin expression in macrophages dampens their inflammatory responsiveness in vitro, but does not modulate M2-regulated pathologies in vivo. Scientific Reports, 2015, 5, 12599.	1.6	29
80	Involvement of connexin43 in acetaminophen-induced liver injury. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1111-1121.	1.8	29
81	DUSP3 Genetic Deletion Confers M2-like Macrophageâ€“Dependent Tolerance to Septic Shock. Journal of Immunology, 2015, 194, 4951-4962.	0.4	28
82	Novel halfâ€life extended antiâ€MIF nanobodies protect against endotoxic shock. FASEB Journal, 2018, 32, 3411-3422.	0.2	27
83	Pharmacologic Activation of LXR Alters the Expression Profile of Tumor-Associated Macrophages and the Abundance of Regulatory T Cells in the Tumor Microenvironment. Cancer Research, 2021, 81, 968-985.	0.4	27
84	Iron Homeostasis and<i>Trypanosoma brucei</i>Associated Immunopathogenicity Development: A Battle/Quest for Iron. BioMed Research International, 2015, 2015, 1-15.	0.9	26
85	Beyond the Mâ€<scp>CSF</scp> receptor â€“ novel therapeutic targets in tumorâ€associated macrophages. FEBS Journal, 2018, 285, 777-787.	2.2	26
86	Macrophage miR-210 induction and metabolic reprogramming in response to pathogen interaction boost life-threatening inflammation. Science Advances, 2021, 7, .	4.7	26
87	Eâ€cadherin: From epithelial glue to immunological regulator. European Journal of Immunology, 2013, 43, 34-37.	1.6	25
88	Immunogenicity of targeted lentivectors. Oncotarget, 2014, 5, 704-715.	0.8	25
89	Molecular Imaging with Kupffer Cell-Targeting Nanobodies for Diagnosis and Prognosis in Mouse Models of Liver Pathogenesis. Molecular Imaging and Biology, 2017, 19, 49-58.	1.3	24
90	B7-1, IFNÎ³ and anti-CTLA-4 co-operate to prevent T-cell tolerization during immunotherapy against a murine T-lymphoma. International Journal of Cancer, 2000, 87, 539-547.	2.3	23

#	Article	IF	Citations
91	Targeting Neuropilin-1 with Nanobodies Reduces Colorectal Carcinoma Development. Cancers, 2020, 12, 3582.	1.7	23
92	Claudinâ€•1, Claudinâ€•2 and Claudinâ€•11 Genes Differentially Associate with Distinct Types of Antiâ€•inflammatory Macrophages <i>In vitro</i> and with Parasiteâ€•and Tumourâ€•elicited Macrophages <i>In vivo</i>. Scandinavian Journal of Immunology, 2012, 75, 588-598.	1.3	22
93	Stromal-targeting radioimmunotherapy mitigates the progression of therapy-resistant tumors. Journal of Controlled Release, 2019, 314, 1-11.	4.8	22
94	Contribution of myeloid cell subsets to liver fibrosis in parasite infection. Journal of Pathology, 2013, 229, 186-197.	2.1	21
95	MIF-Mediated Hemodilution Promotes Pathogenic Anemia in Experimental African Trypanosomosis. PLoS Pathogens, 2016, 12, e1005862.	2.1	20
96	Genetic ablation of IP3receptor 2 increases cytokines and decreases survival ofSOD1G93Amice. Human Molecular Genetics, 2016, 25, 3491-3499.	1.4	19
97	A method for the isolation and purification of mouse peripheral blood monocytes. Journal of Immunological Methods, 2010, 359, 1-10.	0.6	18
98	[3H]IVDE77, a novel radioligand with high affinity and selectivity for the insulin-regulated aminopeptidase. European Journal of Pharmacology, 2013, 702, 93-102.	1.7	18
99	Imaging of Glioblastoma Tumor-Associated Myeloid Cells Using Nanobodies Targeting Signal Regulatory Protein Alpha. Frontiers in Immunology, 2021, 12, 777524.	2.2	18
100	Nanobodies As Tools to Understand, Diagnose, and Treat African Trypanosomiasis. Frontiers in Immunology, 2017, 8, 724.	2.2	17
101	Single-domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophages. Journal of Controlled Release, 2019, 299, 107-120.	4.8	17
102	Inhibition of pannexin1 channels alleviates acetaminophen-induced hepatotoxicity. Archives of Toxicology, 2017, 91, 2245-2261.	1.9	16
103	Active antitumor immunotherapy, with or without B7-mediated costimulation, increases tumor progression in an immunogenic murine T cell lymphoma model. Cancer Immunology, Immunotherapy, 1998, 45, 257-265.	2.0	15
104	STAT of the union: Dynamics of distinct tumorâ€associated macrophage subsets governed by STAT1. European Journal of Immunology, 2014, 44, 2238-2242.	1.6	15
105	Dusp3 deletion in mice promotes experimental lung tumour metastasis in a macrophage dependent manner. PLoS ONE, 2017, 12, e0185786.	1.1	14
106	Reprint of: The non-mammalian MIF superfamily. Immunobiology, 2017, 222, 858-867.	0.8	12
107	A Critical Blimp-1-Dependent IL-10 Regulatory Pathway in T Cells Protects From a Lethal Pro-inflammatory Cytokine Storm During Acute Experimental Trypanosoma brucei Infection. Frontiers in Immunology, 2020, 11, 1085.	2.2	12
108	Presence and regulation of insulin-regulated aminopeptidase in mouse macrophages. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2014, 15, 466-479.	1.0	11

#	Article	IF	Citations
109	Transient Multivalent Nanobody Targeting to CD206-Expressing Cells via PH-Degradable Nanogels. Cells, 2020, 9, 2222.	1.8	11
110	Innate Immune Defense Mechanisms by Myeloid Cells That Hamper Cancer Immunotherapy. Frontiers in Immunology, 2020, 11, 1395.	2.2	11
111	Myeloid tumor necrosis factor and heme oxygenaseâ€1 regulate the progression of colorectal liver metastases during hepatic ischemiaâ€reperfusion. International Journal of Cancer, 2021, 148, 1276-1288.	2.3	11
112	Polymeric nanoreactors for enzyme replacement therapy of MNGIE. Journal of Controlled Release, 2010, 148, e19-e20.	4.8	10
113	Validation of miR-20a as a Tumor Suppressor Gene in Liver Carcinoma Using Hepatocyte-Specific Hyperactive piggyBac Transposons. Molecular Therapy - Nucleic Acids, 2020, 19, 1309-1329.	2.3	9
114	Unsuspected allies: Chemotherapy teams up with immunity to fight cancer. European Journal of Immunology, 2013, 43, 2538-2542.	1.6	7
115	The Quiescin Sulfhydryl Oxidase (hQSOX1b) Tunes the Expression of Resistin-Like Molecule Alpha (RELM-Î± or mFIZZ1) in a Wheat Germ Cell-Free Extract. PLoS ONE, 2013, 8, e55621.	1.1	7
116	Expression of the inhibitory Ly49E receptor is not critically involved in the immune response against cutaneous, pulmonary or liver tumours. Scientific Reports, 2016, 6, 30564.	1.6	7
117	Monocytic myeloid-derived suppressor cells home to tumor-draining lymph nodes via CCR2 and locally modulate the immune response. Cellular Immunology, 2021, 362, 104296.	1.4	7
118	The timing of surgery after neoadjuvant radiotherapy influences tumor dissemination in a preclinical model. Oncotarget, 2015, 6, 36825-36837.	0.8	7
119	Imaging and therapeutic targeting of the tumor immune microenvironment with biologics. Advanced Drug Delivery Reviews, 2022, 184, 114239.	6.6	7
120	Ly49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model. Cancer Immunology, Immunotherapy, 2008, 57, 655-662.	2.0	6
121	Development and Characterization of Nanobodies Targeting the Kupffer Cell. Frontiers in Immunology, 2021, 12, 641819.	2.2	6
122	Ablation of NK Cell Function During Tumor Growth Favors Type 2-Associated Macrophages, Leading to Suppressed CTL Generation. Clinical and Developmental Immunology, 2003, 10, 71-81.	3.3	5
123	Hepatocyte-derived IL-10 plays a crucial role in attenuating pathogenicity during the chronic phase of T. congolense infection. PLoS Pathogens, 2020, 16, e1008170.	2.1	5
124	Multiple effects of transfection with interleukin 2 and/or interferon gamma on the behavior of mouse T lymphoma cells. Clinical and Experimental Metastasis, 1997, 16, 447-459.	1.7	4
125	The wound healing chronicles. Blood, 2012, 120, 499-500.	0.6	3
126	Visceral Leishmaniasis Relapse in HIV Patientsâ€"A Role for Myeloid-Derived Suppressor Cells?. PLoS Neglected Tropical Diseases, 2014, 8, e3132.	1.3	3

#	Article	IF	Citations
127	Myeloid Derived Suppressor Cell Mediated AMPK Activation Regulates Multiple Myeloma Cell Survival. Blood, 2014, 124, 2009-2009.	0.6	3
128	Targeting Cell-Intrinsic and Cell-Extrinsic Mechanisms of Intravasation in Invasive Breast Cancer. Science Signaling, 2014, 7, pe28.	1.6	2
129	RoMo: An efficient strategy for functional mosaic analysis via stochastic Cre recombination and gene targeting in the <i>ROSA26</i> locus. Biotechnology and Bioengineering, 2018, 115, 1778-1792.	1.7	2
130	Myeloid-Derived Suppressor Cells in Multiple Myeloma.. Blood, 2009, 114, 2794-2794.	0.6	2
131	Editorial. Immunobiology, 2012, 217, 1223-1224.	0.8	1
132	Classical and alternative activation of macrophages: different pathways of macrophage-mediated tumor promotion. , 2008, , 139-156.		1
133	Macrophage Differentiation and Activation States in the Tumor Microenvironment. , 2013, , 405-430.		1
134	Origin, phenotype and function of monocyte/macrophage subsets in distinct mammary tumor microenvironments. Cytokine, 2009, 48, 8.	1.4	0
135	Myelomonocytic Subsets in Tumor Microenvironment. , 2014, , 405-423.		0
136	Immunoregulatory Myeloid Cells in the Tumor Microenvironment. SpringerBriefs in Immunology, 2016, , 61-71.	0.1	0
137	Adoptive Transfer of Monocytes Sorted from Bone Marrow. Bio-protocol, 2019, 9, e3134.	0.2	0
138	Title is missing!. , 2020, 16, e1008170.		0
139	Title is missing!. , 2020, 16, e1008170.		0
140	Title is missing!. , 2020, 16, e1008170.		0
141	Title is missing!. , 2020, 16, e1008170.		0